Safety and Performance of the Steroid-Releasing S8 Sinus Implant

NCT ID: NCT01894503

Last Updated: 2018-07-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to assess the safety and performance of the steroid-releasing S8 Sinus Implant when used in post-sinus surgery patients who presented with recurrent sinus obstruction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The S8 PK study was a single-center, open label study treating 5 adult (18 years or older) patients diagnosed with chronic sinusitis, who had undergone prior bilateral total ethmoidectomy and later presented with recurrent nasal obstruction/congestion symptoms and bilateral ethmoid polyposis. The S8 PK study assessed the safety, implant delivery to the ethmoid sinus, and systemic exposure to mometasone furoate (MF) by measuring plasma MF and cortisol concentrations through 30 days post-procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Sinusitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Bilateral in-office placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

S8 Sinus Implant

Bilateral in-office placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses

Group Type EXPERIMENTAL

S8 Sinus Implant (mometasone furoate, 1350 mcg)

Intervention Type DRUG

Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

S8 Sinus Implant (mometasone furoate, 1350 mcg)

Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SINUVA (mometasone furoate) sinus implant

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older
* Diagnosis of chronic sinusitis
* Prior bilateral total ethmoidectomy
* Recurrent sinus obstruction due to polyps grade 2 or higher

Exclusion Criteria

* Required use of mometasone furoate within 2 weeks prior to implant procedure
* Significant scarring or adhesions of the sinus
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Intersect ENT

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Randall Ow, MD

Role: PRINCIPAL_INVESTIGATOR

Sacramento ENT

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sacramento ENT

Sacramento, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P500-0513

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mepolizumab in Nasal Polyposis
NCT01362244 COMPLETED PHASE2